SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-495634"
 

Sökning: id:"swepub:oai:DiVA.org:uu-495634" > Nanoparticles in Cl...

Nanoparticles in Clinical Trials : Analysis of Clinical Trials, FDA Approvals and Use for COVID-19 Vaccines

Namiot, Eugenia D. (författare)
Uppsala universitet,Funktionell farmakologi och neurovetenskap
Sokolov, Aleksandr V. (författare)
Uppsala universitet,Funktionell farmakologi och neurovetenskap
Chubarev, Vladimir N. (författare)
Ltd Liable Co LLC, Adv Mol Technol, Moscow 354340, Russia.
visa fler...
Tarasov, Vadim V. (författare)
Ltd Liable Co LLC, Adv Mol Technol, Moscow 354340, Russia.
Schiöth, Helgi B. (författare)
Uppsala universitet,Funktionell farmakologi och neurovetenskap
visa färre...
 (creator_code:org_t)
2023-01-02
2023
Engelska.
Ingår i: International Journal of Molecular Sciences. - : MDPI. - 1661-6596 .- 1422-0067. ; 24:1
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • Nanoparticles are heterologous small composites that are usually between 1 and 100 nanometers in size. They are applied in many areas of medicine with one of them being drug delivery. Nanoparticles have a number of advantages as drug carriers which include reduced toxic effects, increased bioavailability, and their ability to be modified for specific tissues or cells. Due to the exciting development of nanotechnology concomitant with advances in biotechnology and medicine, the number of clinical trials devoted to nanoparticles for drug delivery is growing rapidly. Some nanoparticles, lipid-based types, in particular, played a crucial role in the developing and manufacturing of the two COVID-19 vaccines-Pfizer and Moderna-that are now being widely used. In this analysis, we provide a quantitative survey of clinical trials using nanoparticles during the period from 2002 to 2021 as well as the recent FDA-approved drugs (since 2016). A total of 486 clinical trials were identified using the clinicaltrials.gov database. The prevailing types of nanoparticles were liposomes (44%) and protein-based formulations (26%) during this period. The most commonly investigated content of the nanoparticles were paclitaxel (23%), metals (11%), doxorubicin (9%), bupivacaine and various vaccines (both were 8%). Among the FDA-approved nanoparticle drugs, polymeric (29%), liposomal (22%) and lipid-based (21%) drugs were the most common. In this analysis, we also discuss the differential development of the diverse groups of nanoparticles and their content, as well as the underlying factors behind the trends.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Nyckelord

nanoparticles
clinical trials
liposomes
clinicaltrials
gov

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy